Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) have been assigned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $102.86.

A number of equities analysts recently commented on AGIO shares. SunTrust Banks reaffirmed a “buy” rating and set a $123.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, July 23rd. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research note on Friday, July 20th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. Canaccord Genuity reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Thursday, August 2nd. Finally, Citigroup started coverage on shares of Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $117.00 price target for the company.

In related news, insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $80.11, for a total transaction of $240,330.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven L. Hoerter sold 2,050 shares of Agios Pharmaceuticals stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $74.92, for a total transaction of $153,586.00. Following the sale, the insider now owns 2,050 shares of the company’s stock, valued at approximately $153,586. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,422 shares of company stock valued at $2,348,788. 3.02% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in AGIO. Wells Fargo & Company MN lifted its holdings in Agios Pharmaceuticals by 2.4% during the 1st quarter. Wells Fargo & Company MN now owns 72,776 shares of the biopharmaceutical company’s stock valued at $5,952,000 after buying an additional 1,711 shares in the last quarter. Rhumbline Advisers lifted its holdings in Agios Pharmaceuticals by 11.1% during the 1st quarter. Rhumbline Advisers now owns 50,151 shares of the biopharmaceutical company’s stock valued at $4,101,000 after buying an additional 5,029 shares in the last quarter. S&CO Inc. bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at about $278,000. Alps Advisors Inc. lifted its holdings in Agios Pharmaceuticals by 39.9% during the 1st quarter. Alps Advisors Inc. now owns 74,717 shares of the biopharmaceutical company’s stock valued at $6,110,000 after buying an additional 21,301 shares in the last quarter. Finally, Frontier Capital Management Co. LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at about $12,769,000. Institutional investors own 93.58% of the company’s stock.

Shares of NASDAQ:AGIO opened at $79.70 on Tuesday. Agios Pharmaceuticals has a 52 week low of $51.62 and a 52 week high of $99.82. The firm has a market capitalization of $4.55 billion, a price-to-earnings ratio of -11.81 and a beta of 1.97.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.43. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The business had revenue of $40.40 million during the quarter, compared to analysts’ expectations of $12.47 million. During the same period last year, the company posted ($1.78) EPS. The business’s revenue was up 257.5% on a year-over-year basis. sell-side analysts anticipate that Agios Pharmaceuticals will post -6.01 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Recommended Story: Market Capitalization and Individual Investors

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.